Navigation Links
Abbott Statement: ACCORD Lipid Results Support Treatment Guidelines for Fibrate Use

ATLANTA, March 14 /PRNewswire-FirstCall/ -- Results were presented today on behalf of the National Heart, Lung and Blood Institute from ACCORD, a study in patients with diabetes that evaluated cardiovascular outcomes in three distinct studies – glycemic control, blood pressure control and lipid control.  In response to data from the ACCORD Lipid study, Abbott issued the following statement:

"The results of ACCORD Lipid were widely expected and not surprising given that two-thirds of patients in the trial would not be treated with fibrates under current guidelines," said Eugene Sun, M.D., vice president, Global Pharmaceutical Development, Abbott.  "While the primary endpoint of the study was not met, the pre-specified subgroup of patients with high triglycerides and low HDL showed potential benefit.  In these patients, fenofibrate plus simvastatin was associated with a 31 percent lower rate of heart attack, stroke and cardiovascular death than simvastatin alone."

The average triglyceride level of a patient that starts fenofibrate in the United States is 302 mg/dL, according to medical claims data.  The median triglyceride level in ACCORD Lipid was 162 mg/dL.  The subgroup of patients in this study with triglycerides at or above 204 mg/dL reflects real-world fibrate usage.

"We are encouraged by the overall safety reported in the ACCORD Lipid study for fenofibrate," added Sun.  "The results are consistent with the safety shown in other studies and support how fibrates are used in treatment today based on guideline recommendations."

The National Cholesterol Education Program (NCEP) treatment guidelines recommend using fibrates with statins in patients with triglycerides above 200 mg/dL when the LDL goal has been met.  

The primary endpoint for ACCORD Lipid (n = 5,518) compared fenofibrate plus simvastatin to simvastatin alone on cardiovascular outcomes of heart attacks, strokes and cardiovascular death.  There was no statistical difference in the primary outcome between the two treatment groups (p = 0.32).  In a pre-specified sub-group of patients with both high triglycerides (at or above 204 mg/dL) and low HDL (at or below 34 mg/dL), there was a 31 percent lower rate of cardiovascular events in the fibrate-plus-statin arm compared to the statin-only arm (p = 0.057 for interaction).

About Abbott

Abbott is a global, broad-based health care company devoted to the discovery, development, manufacture and marketing of pharmaceuticals and medical products, including nutritionals, devices and diagnostics.  The company employs approximately 83,000 people and markets its products in more than 130 countries.

Abbott's news releases and other information are available on the company's Web site at


Back to top



Copyright©2010 PR Newswire.
All rights reserved

Related medicine technology :

1. New Data Demonstrates Abbotts Investigational MitraClip(R) System Has Potential to be a Valuable Treatment Option for Patients With Mitral Regurgitation, the Most Common Heart Valve Condition
2. Abbott Seeks FDA Approval of a New Six-Month 45-mg Formulation of Lupron(R) Depot for the Palliative Treatment of Advanced Prostate Cancer
3. Abbott to Collaborate With GSK on Molecular Diagnostic Test to Select Candidate Patients for Future Skin Cancer Immunotherapy
4. Abbott to Present at Cowen and Company Annual Health Care Conference
5. Abbott Receives U.S. FDA Approval for Heat-Stable Norvir(R) (ritonavir) Tablets
6. Abbott Submits New Automated Ovarian Cancer Test for U.S. Approval
7. Abbott and Pierre Fabre SA Announce Collaboration to Research and Develop Novel Treatments for Cancer
8. Abbotts Ibis Technology Named One of the Top Innovations for 2009 by The Scientist
9. The Deal Names Abbott Top Dealmaker for Second Consecutive Year
10. Abbott Completes Visiogen Acquisition
11. Abbott Cuts Use of Oil and Coal by 35 Percent
Post Your Comments:
(Date:6/24/2016)... , June 24, 2016 Dehaier Medical ... the "Company"), which develops, markets and sells medical devices ... , signed a strategic cooperation agreement with Hongyuan ... "Hongyuan Supply Chain") on June 20, 2016, to develop ... the strategic cooperation agreement, Dehaier will leverage Hongyuan Supply ...
(Date:6/24/2016)... India , June 24, 2016 ... Needles Market by Type (Standard Pen Needles, Safety Pen ... Therapy (Insulin, GLP-1, Growth Hormone), Mode of Purchase (Retail, ... by MarketsandMarkets, This report studies the market for the ... expected to reach USD 2.81 Billion by 2021 from ...
(Date:6/24/2016)... 2016  Arkis BioSciences, a leading innovator in ... durable cerebrospinal fluid treatments, today announced it has ... is led by Innova Memphis, followed by Angel ... investors.  Arkis, new financing will accelerate the commercialization ... release of its in-licensed Endexo® technology. ...
Breaking Medicine Technology:
(Date:6/27/2016)... (PRWEB) , ... June 27, 2016 , ... ... District , the only authorized OSHA Training Institute Education Center headquartered in Northern ... protecting their workers from extreme heat at their worksites. Employers with workers ...
(Date:6/27/2016)... ... 2016 , ... "FCPX editors can now reveal their media with growing colorful ... Christina Austin - CEO of Pixel Film Studios. , ProSlice Color brings the ... can now reveal the media of their split screens with growing colorful panels. , ...
(Date:6/27/2016)... ... June 27, 2016 , ... ... announced today its affiliation with Tennessee Counseling Association. This new relationship ... of the Tennessee Counseling Association, adding exclusive benefits and promotional offers. , "TCA ...
(Date:6/27/2016)... ... June 27, 2016 , ... ... strategic partnership with Connance, a healthcare industry leader providing predictive analytics to ... technology combine to provide health systems, hospitals and ambulatory surgical centers with ...
(Date:6/27/2016)... ... June 27, 2016 , ... A revolution is ... emergency ambulance transport experience for the millions of people who require these medical ... the taxi industry through the use of technology. Now, SmartEMS has put forth ...
Breaking Medicine News(10 mins):